Zealand Pharma A/S (OTCMKTS:ZLDPF) Hits New 52-Week High at $129.35

Zealand Pharma A/S (OTCMKTS:ZLDPF) hit a new 52-week high during trading on Friday . The company traded as high as $129.35 and last traded at $129.35, with a volume of 908 shares trading hands. The stock had previously closed at $124.45.

Wall Street Analysts Forecast Growth

ZLDPF has been the topic of several recent research reports. BTIG Research initiated coverage on Zealand Pharma A/S in a research report on Thursday, March 7th. They set a “buy” rating on the stock. Cantor Fitzgerald began coverage on Zealand Pharma A/S in a report on Tuesday, May 21st. They set an “overweight” rating on the stock.

Zealand Pharma A/S Price Performance

The firm’s 50 day moving average is $94.45 and its 200 day moving average is $83.27. The company has a debt-to-equity ratio of 0.10, a quick ratio of 12.28 and a current ratio of 12.30.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last released its quarterly earnings results on Thursday, May 16th. The company reported ($0.54) earnings per share for the quarter. The firm had revenue of $2.20 million during the quarter. Zealand Pharma A/S had a negative return on equity of 36.96% and a negative net margin of 213.77%. As a group, equities research analysts anticipate that Zealand Pharma A/S will post -2.54 earnings per share for the current year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.